Limitations, agreements, and source contact

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer · Source last updated 2026-01-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

CTRinfo@dsi.com

organization

Daiichi Sanyko, Inc

phone

908-992-6400

title

Contact for Clinical Trial Information

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice